NS

Neeta Sudhir Akre

Active Director Director DIN 08692149
DIN 08692149 First appointment Feb 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2020
Shareholding value •••• Premium profile

About Neeta Sudhir Akre

Data last updated:

Neeta Sudhir Akre is a Director at Biollios Pharmaceutical Private Limited (since 2020). The company operates in Pharma. Biollios Pharmaceutical Private Limited reported revenue of ₹1.6 Lakh (FY 2025).

DIN 08692149
Primary Designation Director
Industry Pharma
First Appointment 06 Feb 2020
Oldest Company Age 6 yrs
Largest company Biollios Pharmaceutical Private Limited · ₹1.6 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Feb 20202020₹1.6 Lakh (FY 2025)Active

Board colleagues of Neeta Sudhir Akre

Directorship timeline

Open interactive timeline →
Biollios Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Neeta Sudhir Akre

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neeta Sudhir Akre

Neeta Sudhir Akre currently holds 1 directorship: Biollios Pharmaceutical Private Limited (Director, since 06 Feb 2020, revenue ₹1.6 Lakh (FY 2025)).

Neeta Sudhir Akre was first appointed on 06 Feb 2020 as Director at Biollios Pharmaceutical Private Limited.

The current boards of Neeta Sudhir Akre's companies include Sudhir Bhagwantrao Akre (Biollios Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available